Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB2 | O60825 | 7/20 | 0.51 |
| ▸ | PFKFB3 | Q16875 | 7/20 | 0.51 |
| ▸ | PFKFB1 | P16118 | 6/20 | 0.51 |
| ▸ | AS3MT | Q9HBK9 | 5/20 | 0.51 |
| ▸ | NSD2 | O96028 | 3/20 | 0.51 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 8/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10095382 | 0.93 | RORC (0.45) | PFKFB2PFKFB3PFKFB1AS3MTNSD2 | |
| SCHEMBL10095424 | 0.90 | MEN1 (0.45) | PFKFB2PFKFB3PFKFB1AS3MTNSD2 | |
| SCHEMBL10095377 | 0.88 | PFKFB2 (0.55) | PFKFB2PFKFB3PFKFB1AS3MTNSD2 | |
| SCHEMBL982113 | 0.86 | SMN1; SMN2 (0.45) | PFKFB2PFKFB3PFKFB1AS3MTNSD2 | |
| SCHEMBL10095390 | 0.84 | SMN1; SMN2 (0.41) | PFKFB2PFKFB3PFKFB1AS3MTNSD2 | |
| SCHEMBL2881493 | 0.84 | PARP10 (0.37) | PFKFB2PFKFB3PFKFB1AS3MTNSD2 | |
| SCHEMBL2881494 | 0.83 | APP (0.41) | PFKFB2PFKFB3PFKFB1AS3MTNSD2 | |
| SCHEMBL10095412 | 0.83 | PGR (0.45) | PFKFB2PFKFB3PFKFB1AS3MTNSD2 | |
| SCHEMBL10095379 | 0.83 | CYP11B2 (0.38) | PFKFB2PFKFB3PFKFB1AS3MTNSD2 | |
| SCHEMBL10095401 | 0.81 | HTT (0.39) | HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009142-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | PFKFB2 4129/4885PFKFB3 4055/4885PFKFB1 4133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.